Medical technology company Terumo BCT and PwC Belgium announced a new collaboration focused on driving equitable and sustainable access to advanced therapy medicinal products (ATMPs) in Europe, which will include a flagship event in Brussels.
The event, titled “Unlocking patient access to advanced cell therapies” will take place on December 11, 2025, at PwC Belgium’s headquarters in Diegem, Brussels. It will convene senior leaders from across the health care spectrum — from R&D and manufacturing to regulators, payers and patient advocates. Structured around a series of TED-style talks and a high-level panel discussion, the event will explore the root causes of restricted access to ATMPs and spotlight innovative models of collaboration.
PwC/Terumo partnership combines PwC Belgium’s health care systems expertise and network of public and private stakeholders with Terumo BCT’s innovation in blood component, therapeutic apheresis and cellular technologies.
Subscribe to our e-Newsletters
Stay up to date with news, articles and insights relevant to cell and gene therapy development and manufacturing. Plus, get special offers from Cell & Gene Therapy Review delivered right to your inbox!
Sign up now!